Updated on 4 October 2012
Audeo Oncology has appointed three new members to its board of directors
Singapore: Audeo Oncology, which has offices in Australia and the US, has appointed Ms Leigh Bonney, Dr Susan Kelley and Dr David U'Prichard to its board of directors.
Ms Leigh Bonney has held senior positions in strategy and finance in the healthcare industry for much of her career, including 15 years at Pfizer, from which she retired in 2011. She served as the chief financial officer of Pfizer Global Research and Development among other positions at the company. Prior to Pfizer, she worked for McKinsey, where she served as a consultant for clients within a number of industries, including healthcare and pharmaceuticals. She is currently the chief financial officer of the Leona M. and Harry B. Helmsley Charitable Trust. Ms Leigh Bonney has agreed to chair the audit committee of Audeo.
Dr Susan Kelley is a medical oncologist who has held fellowships at the Dana-Farber Cancer Institute, Harvard Medical School and Yale School of Medicine. Dr Kelly has held senior positions in the pharmaceutical industry such as vice president, Global Strategic Drug Development, Oncology and Metabolics with Bayer-Schering Pharmaceuticals, and Therapeutic Area Head-Oncology with Bayer Pharmaceuticals. She has agreed to chair the nominations and corporate governance committee of Audeo.
Dr David U'Prichard has had an extensive career in the management of drug discovery and development and currently advises life sciences companies as president of Druid Consulting. Previously, he served as CEO of 3-Dimensional Pharmaceuticals. In addition, he held the positions of president and chairman of Research and Development for SmithKline Beecham Pharmaceuticals and executive vice president and international research director and member of the Board and Management of Zeneca Pharmaceuticals. He has agreed to chair the compensation committee of Audeo.
Commenting on the appointments, Mr Stephen Hill, chairman of Audeo, said, "We are extremely pleased and very fortunate to be joined by individuals with deep experience in the pharmaceutical and biotech industry. Leigh, Susan, and David will bring comprehensive expertise across finance, corporate strategy, oncology, drug discovery, and clinical development."